Not repackaged. Not drop-shipped. We synthesize it. On a parallel recombinant system, purified to ≥98%, confirmed by ESI-MS. Every vial has a batch number you can trace back to the resin.
The sequences everyone wants. The difference is we don't buy them from the same two Chinese bulk houses and divide them into smaller vials. Each batch is a discrete synthesis event.
Highest-demand item in the catalog. Binds pancreatic beta cells and hypothalamic neurons with the same pathway equivalence as the FDA-approved reference.
31 amino acids. 4114 Da. ≥98% HPLC. ESI-MS confirmed.
Research dosing: 0.25–2.4 mg SC weekly. Weight loss 12–15% in model systems.
Second-highest demand. Simultaneous GIPR and GLP-1R activation. This is not a generic GLP-1 analog — dual agonism is the current edge of metabolic research, and most suppliers don't even stock it because the synthesis is annoying.
39 amino acids. 4814 Da. Research dosing: 2.5–15 mg SC weekly.
GLP-1R / GIPR / GCGR. Highest-margin item. Limited global suppliers because the sequence is long and the synthesis yield is punishing.
Strongest efficacy in the GLP class. Weight loss 15–22% in model systems. 43 amino acids. ~5000 Da.
Propiolamide-modified peptides. Reversible covalent warheads extending duration from hours to weeks. Patentable as novel chemical entities. Not available from any other supplier.
Standard peptides degrade within minutes to hours in plasma. The propiolamide warhead is an N-propargylacrylamide derivative — a Michael acceptor with moderated electron-withdrawing character. When it encounters a nucleophilic thiol (cysteine) or amine (lysine) on the target receptor, it undergoes Michael addition, forming a covalent adduct.
Crucially: this bond is reversible. The adduct hydrolyzes over 2–4 weeks, releasing the drug without permanent receptor damage. Think Velcro, not superglue. The receptor itself becomes the depot — no albumin binding, no large injection volumes, no albumin interference.
Semax scaffold + N-terminal acetyl-propiolamide. Covalent attachment to TrkB extracellular domain cysteines (Cys345, Cys300 in CRD2). Prevents ligand dissociation, extending ERK1/2 and PI3K/Akt signaling for weeks.
Deliverable-based engagements. Not vibes. Not workshops. Compounds, data, and documentation.